The FTXH ETF is a passive product designed to track the performance of the Nasdaq US Smart Pharmaceuticals Index. It selects index constituents from US pharmaceutical and biotech companies, reflecting factors such as profitability, asset efficiency, momentum and cash flow.

Unlike broad market products, it suits long-term investors who want exposure to the growth drivers of the US pharmaceutical industry and are willing to accept the sector-specific risks that come with it.

It is a passive (index-tracking) ETF managed by First Trust.

The FTXH ETF replicates the index's constituents and weights. From among US pharmaceutical and biotech companies, the index selects stocks by considering liquidity and a range of financial and market characteristics, and it sets weights by reflecting cash flow. As a result, it offers exposure spread across multiple companies in the sector rather than to a single new drug or a single company.

• A stock selection method that reflects both financial and market characteristics
• An index-tracking structure concentrated in the pharmaceutical and biotech industries

Assets under management (AUM) stand at $1.2B, and the total expense ratio is 0.60% per year.

Trading liquidity and bid-ask spreads can vary with market conditions, so when placing a trade, it is worth checking the trading terms along with the gap between market price and net asset value.

The performance of the FTXH ETF can be influenced by earnings expectations for the pharmaceutical industry, news on new drug development, the drug pricing environment and regulatory interpretation. Within the sector, large pharmaceutical companies and biotech firms have different business characteristics, so their reactions to market conditions can differ.

Fund flows into the FTXH ETF can reflect the market's views on a preference for defensive sectors, growth expectations and the regulatory environment. Changes in drug pricing policy or patents, as well as geopolitical variables, can affect pharmaceutical companies' earnings outlook and investor sentiment, so related disclosures and industry news should be monitored.

Sector-specific exposure and index-based diversification are its strengths, but investors should be mindful of sector volatility driven by regulation, patents and development outcomes.

In the table, the VFH ETF targets the financial sector, the ONEQ ETF the Nasdaq Composite market, the VIS ETF the industrial sector, the IYF ETF US financials and the FV ETF a concentrated equity strategy, so their underlying exposure and investment objectives differ from those of the FTXH ETF. This comparison table is a reference for broadly contrasting fee burden, asset size and distribution characteristics, and it does not imply a direct substitute for the pharmaceutical industry. Information on listed products in a similar category is limited in the candidate list provided, so it is worth checking each product's prospectus as well.

When considering the FTXH ETF, you should check your purpose for gaining pharmaceutical industry exposure, long-term holding costs, distribution policy and currency effects together. Because it is a sector-specific product, changes in regulation and the competitive environment matter for investment decisions as much as news on individual companies.

Uncertainty in new drug development, changes in patent protection, generic drug competition, and policies on drug pricing and approvals can shift profitability expectations across the pharmaceutical industry. When market anxiety rises, it is also worth checking the gap between market price and net asset value for sector-specific products, as well as trading conditions.

The FTXH ETF is a product to consider if you want index-based exposure to the US pharmaceutical and biotech industries. However, it calls for an approach that understands its sector-concentrated structure, which differs from broad market products, does not interpret quarterly distributions as a guarantee of returns, and reviews regulatory, patent and currency risks within a long-term asset allocation.